Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point (Q37082159)

18 August 2017

1 reference

title

Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point (English)

1 reference

18 August 2017

0 references

1 reference

6

Jeffrey H Kordower

1 reference

18 August 2017

5

Mark Tuszynski

1 reference

18 August 2017

Raymond T Bartus

1

1 reference

18 August 2017

Christopher D Herzog

2

1 reference

18 August 2017

Kathie Bishop

3

1 reference

18 August 2017

Jeffrey M Ostrove

4

1 reference

18 August 2017

Mehdi Gasmi

7

1 reference

18 August 2017

publication date

1 January 2007

1 reference

Parkinsonism and Related Disorders

18 August 2017

published in

1 reference

18 August 2017

volume

13 Suppl 3

1 reference

18 August 2017

page(s)

S469-77

1 reference

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Point source concentration of GDNF may explain failure of phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Occurrence of leukaemia following gene therapy of X-linked SCID.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Neurotrophic factors: can the degenerating brain be induced to heal itself?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Crossroads in GDNF therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Convective delivery of glial cell line-derived neurotrophic factor in the human putamen

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Neurotrophin receptor-based strategies for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970052-X

7 January 2021

10.1016/S1353-8020(08)70052-X

Identifiers

DOI

1 reference

18 August 2017

1 reference